Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission

NCT00761579 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone

Sponsor

Janssen Korea, Ltd., Korea